Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | KEYNOTE-199: an update on pembrolizumab for mCRPC

Emmanuel Antonarakis, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, gives us an update on the KEYNOTE-199 trial (NCT02787005), using pembrolizumab as monotherapy in men with metastatic castration-resistant prostate cancer (mCRPC), and the potential of combining pembrolizumab with docetaxel, enzalutamide or olaparib. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.